Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 23 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
• Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT04477486Phase 2Results posted
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT04476043Phase 2Results posted
• A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic ImpairmentCompletedNCT04473664Phase 1Results posted
• Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsCompletedNCT04472650Phase 1Results posted
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompletedNCT04471428Phase 3Results posted
• The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy MalesCompletedNCT04470908Phase 1Results posted
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction CancersActive, not recruitingNCT04460937Phase 1Results posted
• A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy ParticipantsCompletedNCT04459598Phase 1Results posted
• A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04459585Early Phase 1Results posted
• GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)CompletedNCT04456998Phase 2Results posted
• A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease StateCompletedNCT04451772Phase 2Results posted
• A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)CompletedNCT04447755Phase 2Results posted
• Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHDTerminatedNCT04446182Phase 2Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingNCT04446117Phase 3Results posted
• A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult ParticipantsCompletedNCT04441255Phase 1Results posted
• Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19CompletedNCT04440007Phase 2Results posted
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)TerminatedNCT04439071Phase 2/3Results posted
• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsCompletedNCT04430855Phase 2Results posted
• Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)CompletedNCT04428151Phase 2Results posted
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedNCT04427072Phase 3Results posted
• Infigratinib in Recurrent High-Grade Glioma PatientsTerminatedNCT04424966Early Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With COVID-19CompletedNCT04421027Phase 3Results posted
• Tofacitinib for Treatment of Moderate COVID-19TerminatedNCT04415151Phase 2Results posted
• Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa TreatmentTerminatedNCT04414514Phase 2Results posted
• TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompletedNCT04413617Phase 2Results posted
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)CompletedNCT04411641Phase 3Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)CompletedNCT04410991Phase 3Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)CompletedNCT04410978Phase 3Results posted
• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2Results posted
• TD-0903 for ALI Associated With COVID-19CompletedNCT04402866Phase 2Results posted
• Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
• Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
• Trial of Imatinib for Hospitalized Adults With COVID-19TerminatedNCT04394416Phase 3Results posted
• Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results posted
• Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsCompletedNCT04382586Phase 2Results posted
• Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04380688Phase 2Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary InjuryCompletedNCT04375397Phase 2Results posted
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSCompletedNCT04374149Phase 2Results posted
• Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedNCT04373369Phase 2Results posted
• A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibCompletedNCT04366713Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
• Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCompletedNCT04362072Phase 4Results posted
• Itacitinib in Advanced Hepatocellular CarcinomaCompletedNCT04358185Phase 1Results posted
• Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal CancerCompletedNCT04355156Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results posted
• Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04346199Phase 2Results posted
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedNCT04338061Phase 3Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedNCT04338022Phase 3Results posted
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
• Study Of Intrabucally Administered Electromagnetic Fields and RegorafenibTerminatedNCT04327700Phase 2Results posted
• AflacLL1901 (CHOA-AML)TerminatedNCT04326439Phase 2Results posted
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)CompletedNCT04316182Phase 2Results posted
• Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansCompletedNCT04313634Phase 2Results posted
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host DiseaseCompletedNCT04294641Phase 2Results posted
• Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical SurgeryTerminatedNCT04294277Phase 2Results posted
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT04283669Phase 2Results posted
• A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Phase 2Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
• Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results posted
• Renal Impairment Study of PF-06700841CompletedNCT04260464Phase 1Results posted
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3Results posted
• Tofacitinib for Immune Skin Conditions in Down SyndromeCompletedNCT04246372Phase 2Results posted
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results posted
• A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04240002Phase 1/2Results posted
• Ibrutinib and Rituxan for Chronic GVHDTerminatedNCT04235036Phase 2Results posted
• Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsCompletedNCT04233567Phase 2Results posted
• A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the BodyTerminatedNCT04232839Phase 1Results posted
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyTerminatedNCT04230304Phase 2Results posted
• Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedNCT04228042Phase 1/2Results posted
• A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic FunctionCompletedNCT04226833Phase 1Results posted
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedNCT04223635Early Phase 1Results posted
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
• Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the ExtremitiesTerminatedNCT04220229Phase 1/2Results posted
• ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorTerminatedNCT04216563Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingNCT04211337Phase 3Results posted
• Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
• A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.TerminatedNCT04209465Phase 1Results posted
• Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast CancerCompletedNCT04205903Phase 1Results posted
• Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment FailureCompletedNCT04205799Phase 2Results posted
• Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedNCT04204902Phase 1Results posted
• Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaActive, not recruitingNCT04200443Phase 2Results posted
• A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT04200365Phase 2Results posted

← Tyrosine Kinase Inhibitors overview